Diagnostic importance of S100A9 and S100A12 in breast cancer

Biomedicine and Pharmacotherapy

Volumn 76, Issue , 2015, Pages 52-56

  Gunaldi, Meral ^a   Okuturlar, Yildiz ^a   Gedikbasi, Asuman ^a   Akarsu, Cevher ^a   Karabulut, Mehmet ^a   Kural, Alev ^a  

^a BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Breast cancer; Inflammation; S100A12; S100A9; Target marker

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CALGRANULIN B; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN S 100; PROTEIN S100A12; UNCLASSIFIED DRUG; CALGRANULIN C; TUMOR MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOCYTOSIS; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; PERINEURAL INVASION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SMOKING; SYSTEMIC THERAPY; THROMBOCYTOSIS; TUMOR VOLUME; AGED; BLOOD; BREAST NEOPLASMS; CASE CONTROL STUDY; MIDDLE AGED; PATHOLOGY;

AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CALGRANULIN B; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; S100A12 PROTEIN;

EID: 84949293425     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.10.029     Document Type: Article

References (38)

1. Ross J.S., Linette G.P., Stec J., Clark E., Ayers M., Leschly N., et al. Breast cancer biomarkers and molecular medicine. Expert Rev. Mol. Diagn. 2003, 3:573-585.
2. Xia P., Wang H.J., Geng T.T., Xun X.J., Zhou W.J., Jin T.B., et al. Mitochondrial DNA levels in blood and tissue samples from breast cancer patients of different stages. Asian Pac. J. Cancer Prev. 2014, 15:1339-1344.
3. Hu Q., Luo Z., Xu T., Zhang J.Y., Zhu Y., Chen W.X., et al. FOXA1: a promising prognostic marker in breast cancer. Asian Pac. J. Cancer Prev. 2014, 15:11-16.
4. Leanderson T., Ivars F. S100A9 and tumor growth. Oncoimmunology 2012, 1:1404-1405.
5. Gebhardt C., Nemeth J., Angel P., Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 2006, 72:1622-1631.
6. Garcia A.F., Garcia W., Nonato M.C., Araujo A.P. Structural stability and reversible unfolding of recombinant porcine S100A12. Biophys. Chem. 2008, 134:246-253.
7. Zhao F.T., Jia Z.S., Yang Q., Song L., Jiang X.J. S100A14 promotes the growth and metastasis of hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 2013, 14:3831-3836.
8. Yang Z., Tao T., Raftery M.J., Youssef P., Di Girolamo N., Geczy C.L. Proinflammatory properties of the human S100 protein S100A12. J. Leukocyte Biol. 2001, 69:986-994.
9. Dabritz J., Langhorst J., Lugering A., Heidemann J., Mohr M., Wittkowski H., et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm. Bowel Dis. 2013, 19:1130-1138.
10. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 2001, 33:637-668.
11. Heizmann C.W., Fritz G., Schafer B.W. S100 proteins: structure, functions and pathology. Front. Biosci. 2002, 7:d1356-d1368.
12. Roth J., Vogl T., Sorg C., Sunderkotter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol. 2003, 24:155-158.
13. Mueller A., Schafer B.W., Ferrari S., Weibel M., Makek M., Hochli M., et al. The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J. Biol. Chem. 2005, 280:29186-29193.
14. Kriajevska M., Tarabykina S., Bronstein I., Maitland N., Lomonosov M., Hansen K., et al. Metastasis-associated Mts1 (S100A4) protein modulates protein kinase C phosphorylation of the heavy chain of nonmuscle myosin. J. Biol. Chem. 1998, 273:9852-9856.
15. Salama I., Malone P.S., Mihaimeed F., Jones J.L. A review of the S100 proteins in cancer. Eur. J. Surg. Oncol. 2008, 34:357-364.
16. Turovskaya O., Foell D., Sinha P., Vogl T., Newlin R., Nayak J., et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008, 29:2035-2043.
17. Kim H.J., Kang H.J., Lee H., Lee S.T., Yu M.H., Kim H., et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J. Proteome Res. 2009, 8:1368-1379.
18. Hermani A., Hess J., De Servi B., Medunjanin S., Grobholz R., Trojan L., et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin. Cancer Res. 2005, 11:5146-5152.
19. Tavassoli F., Devilee P., Organization W.H. Tumours of the breast and female genital organs-pathology and genetics. World Health Organization Classification of Tumours 2003, IARC Press, Lyon, France.
20. Huober J., von Minckwitz G., Denkert C., Tesch H., Weiss E., Zahm D.M., et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res. Treat. 2010, 124:133-140.
21. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech. 2003, 60:540-551.
22. Marenholz I., Heizmann C.W., Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun. 2004, 322:1111-1122.
23. Eckert R.L., Broome A.M., Ruse M., Robinson N., Ryan D., Lee K. S100 proteins in the epidermis. J. Invest. Dermatol. 2004, 123:23-33.
24. Thorey I.S., Roth J., Regenbogen J., Halle J.P., Bittner M., Vogl T., et al. The Ca2+-binding proteins S100A8 and S100A9 are encoded by novel injury-regulated genes. J. Biol. Chem. 2001, 276:35818-35825.
25. Ryckman C., Vandal K., Rouleau P., Talbot M., Tessier P.A. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J. Immunol. 2003, 170:3233-3242.
26. Huang X., Zeng Y., Xing X., Zeng J., Gao Y., Cai Z., et al. Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection. Proteome Sci. 2014, 12:22.
27. Arai K., Teratani T., Nozawa R., Yamada T. Immunohistochemical investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation. Oncol. Rep. 2001, 8:591-596.
28. Arai K., Yamada T., Nozawa R. Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med. Oncol. 2000, 17:183-188.
29. Arai K., Teratani T., Kuruto-Niwa R., Yamada T., Nozawa R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur. J. Cancer 2004, 40:1179-1187.
30. Ito Y., Arai K., Ryushi N., ozawa Y., oshida H., Tomoda C., et al. S100A9 expression is significantly linked to dedifferentiation of thyroid carcinoma. Pathol. Res. Pract. 2005, 201:551-556.
31. Ichikawa M., Williams R., Wang L., Vogl T., Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol. Cancer Res. 2011, 9:133-148.
32. McKiernan E., McDermott E.W., Evoy D., Crown J., Duffy M.J. The role of S100 genes in breast cancer progression. Tumour Biol. 2011, 32:441-450.
33. Su Y.J., Xu F., Yu J.P., Yue D.S., Ren X.B., Wang C.L. Up-regulation of the expression of S100A8 and S100A9 in lung adenocarcinoma and its correlation with inflammation and other clinical features. Chin. Med. J. 2010, 123:2215-2220.
34. Jiang L., He L., Fountoulakis M. Comparison of protein precipitation methods for sample preparation prior to proteomic analysis. J. Chromatogr. A 2004, 1023:317-320.
35. Park M.R., Wang E.H., Jin D.C., Cha J.H., Lee K.H., Yang C.W., et al. Establishment of a 2-D human urinary proteomic map in IgA nephropathy. Proteomics 2006, 6:1066-1076.
36. Cross S.S., Hamdy F.C., Deloulme J.C., Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005, 46:256-269.
37. Du X.M., Chang H., Sun H.Y., Zhang J.Y., Gao Y., Shen B. Expression and clinical significance of calcium-binding protein S100A9 in breast cancer. Xi bao yu fen zi mian yi xue za zhi (Chin. J. Cell. Mol. Immunol.) 2012, 28:637-639.
38. Thierolf M., Hagmann M.L., Pfeffer M., Berntenis N., Wild N., Roessler M., et al. Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker. Proteomics Clin. Appl. 2008, 2:11-22.